AstraZeneca Results Presentation Deck
Pipeline catalysts for 2022 - 2023
Industry leading news flow
ww
Regulatory
decision
Regulatory
submission
and/or
acceptance
Key Phase III
data readouts
H1 2022
Lynparza - breast cancer (adjuvant) (US)
Enhertu - HER2+ breast cancer (2L) (US)
Brilique - stroke (THALES) (CN)
Forxiga - chronic kidney disease (CN)
Fasenra-nasal polyps (US)
Saphnelo - lupus (SLE) (EU)
tezepelumab - asthma (EU, JP)
Ultomiris-gMG (US)
Imfinzi +/- tremelimumab - liver cancer (1L)
(HIMALAYA)
Imfinzi - biliary tract cancer (TOPAZ-1)
Lynparza - prostate cancer (1L) (US, JP)
Enhertu - HER2-low breast cancer (3L) (DESTINY-
Breast04)
PT027-asthma (US)
Vaxzevria-COVID-19 (US)
Evusheld-COVID-19 outpatient treatment (EU, JP)
nirsevimab - respiratory syncytial virus
Ultomiris - subcutaneous, PNH and aHUS (EU)
Imfinzi - NSCLC (1L) (PEARL)
Imfinzi - cervical cancer (CALLA)
Imfinzi - NSCLC (unresectable Stg. III) (PACIFIC-2)
Enhertu - HER2-low breast cancer (3L) (DESTINY-
Breast04)
Farxiga - HFPEF (DELIVER)
Ultomiris - NMOSD
H2 2022
Tagrisso - EGFRm NSCLC (adjuvant) (JP)
Imfinzi +/- tremelimumab - NSCLC (1L)
Lynparza - ovarian cancer (1L) (CN)
Lynparza - prostate cancer (1L) (EU)
Lynparza - breast cancer (adjuvant) (EU, JP)
Enhertu - HER2+ breast cancer (2L) (EU, JP)
Enhertu - HER2+ gastric cancer (2L) (EU)
Koselugo - NF1-PN (JP)
Ultomiris-gMG (EU, JP)
Ultomiris - subcutaneous, PNH and aHUS (US)
Imfinzi - NSCLC (unresectable, Stg. III) (PACIFIC-2)
Imfinzi - NSCLC (1L) (PEARL)
Imfinzi - cervical cancer (CALLA)
Imfinzi - liver cancer (locoregional) (EMERALD-1)
Enhertu - HER2+ breast cancer (3L) (DESTINY-Breast02)
Calquence - CLL (ELEVATE-TN) (JP)
Koselugo - NF1-PN (SPRINT) (CN)
Farxiga - HFpEF (DELIVER)
eplontersen – hATTR-PN (NEURO-TTRansform)
Ultomiris-NMOSD
ALXN1840-Wilson disease
Imfinzi - SCLC (limited-stage) (ADRIATIC)
Imfinzi - liver cancer (locoregional) (EMERALD-1)
Enhertu - HER2+ breast cancer (3L) (DESTINY-Breast02)
Calquence - MCL (1L) (ECHO)
eplontersen – hATTR-PN (NEURO-TTRansform)
Fasenra-HES (NATRON)
Fasenra- EOE (MESSINA)
acoramidis - ATTR-CM (JP)
Tagrisso - EGFRm NSCLC (1L) (FLAURA2)
Tagrisso - EGFRm NSCLC (unresectable Stg. III) (LAURA)
Imfinzi - limited-stage SCLC (ADRIATIC)
Imfinzi- bladder cancer (1L) (NILE)
Imfinzi - bladder cancer (muscle invasive) (NIAGARA)
Imfinzi - liver cancer (adjuvant) (EMERALD-2)
Imfinzi - NSCLC (neoadjuvant) (AEGEAN)
Lynparza - breast cancer (adjuvant) (CN)
Lynparza - colorectal cancer (1L) (LYNK-003)
capivasertib - TNBC (locally adv./met.) (CAPItello-290)
capivasertib - HR+/HER2-neg. breast cancer (CAPItello-291)
Dato-DXd - NSCLC (3L) (TROPION-Lung01)
Tagrisso - EGFRm NSCLC (1L) (FLAURA2)
Tagrisso - EGFRm NSCLC (unresectable Stg. III) (LAURA)
Imfinzi- bladder cancer (muscle invasive) (NIAGARA)
Imfinzi - NSCLC (neoadjuvant) (AEGEAN)
Imfinzi - liver cancer (adjuvant) (EMERALD-2)
Imfinzi - bladder cancer (1L) (NILE)
2023
Lynparza - colorectal cancer (1L) (LYNK-003)
Lynparza + Imfinzi - ovarian cancer (1L) (DUO-O)
Lynparza + Imfinzi- endometrial cancer (1L) (DuO-E)
Enhertu - HER2oe gastric cancer (DESTINY-Gastric03)
Enhertu - HER2m NSCLC (unresectable) (DESTINY-Lung02)
Enhertu - HER2-low breast cancer (2L) (DESTINY-Breast06)
EGFRm = epidermal growth factor receptor mutated; HER2-low = human epidermal growth factor receptor 2 low; Stg. = stage; HFpEF = heart failure with preserved ejection faction; NMOSD = neuromyelitis
optica spectrum disorder; MCL = mantle cell lymphoma; HES = hyper eosinophilic syndrome; EOE = eosinophilic oesophagitis; TNBC = triple negative breast cancer; adv = advanced; met = metastatic; HR+ =
32 hormone receptor positive; HER2-neg = human epidermal growth factor receptor 2 low; HER2oe human epidermal growth factor receptor over expressing; HER2m = human epidermal growth factor mutant;
CRwNP = chronic rhinosinusitis with nasal polyps; EGPA= eosinophilic granulomatosis with polyangiitis.
Oncology BioPharmaceuticals Rare Disease
Fasenra- EOE (MESSINA)
Fasenra- EGPA (MANDARA)
Fasenra-HES (NATRON)
Fasenra - severe asthma (CN) (MIRACLE)
acoramidis - ATTR-CM (JP)
danicopan - PNH with extravascular haemolysis
Calquence - CLL (1L) (AC-CL-311)
capivasertib - TNBC (locally adv/met) (CAPItello-290)
capivasertib - HR+ HER2-neg breast cancer (1L)
(CAPItello-291)
camizestrant - HR+ HER2-neg breast cancer (SERENA-6)
Dato-DXd - NSCLC (3L) (TROPION-Lung01)
Farxiga - myocardial infarction (DAPA-MI)
roxadustat - anaemia of myelodysplastic syndrome
Fasenra - severe asthma (MIRACLE)
Fasenra - CRwNP (ORCHID)
Fasenra- EGPA (MANDARA)
Fasenra - bullous pemphigoid (FJORD)
Soliris - guillain-barre syndrome (JP)
danicopan - PNH with extravascular haemolysisView entire presentation